Five Prime Therapeutics (FPRX) Misses Q3 EPS by 14c

Five Prime Therapeutics (NASDAQ: FPRX) reported Q3 EPS of ($0.74), $0.14 worse than the analyst estimate of ($0.60). Revenue for the quarter came in at $2.05 million versus the consensus estimate of $3.41 million.

For earnings history and earnings-related data on Five Prime Therapeutics (FPRX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SanDisk upgraded at JPMorgan after investor day; shares climb
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79